Abstract:Background: Immune checkpoint inhibitors are new immunotherapy drugs globally used for many malignancies, including renal cell carcinoma. Myocarditis as an immune-related adverse event is rare but highly fatal, suggesting that its frequency may be higher than reported. This paper describes a case of myocarditis that developed asymptomatically following ipilimumab and nivolumab combination therapy for renal cell carcinoma. Case presentation: A 71-year-old Asian man who presented to hospital with fever, fatigue, and weight loss of approximately 10 kg within 2 months was diagnosed with Xp.11.2 translocation renal cell carcinoma. Computed tomography revealed multiple lung masses, mediastinal lymph node enlargement, and a level II tumor thrombus reaching the inferior vena cava (cT3bN0M1; International Metastatic Renal Cell Carcinoma Database Consortium, poor risk). Ipilimumab/nivolumab combination therapy was started as induction therapy. The patient experienced acute interstitial nephritis as an immune-related adverse event after treatment initiation; however, a good response to steroid therapy was observed. The antitumor effect of the immunotherapy was notable. Although he experienced pulmonary embolism, it seemed asymptomatic and harmless; thus, a second infusion was introduced. From the eighth day, he demonstrated rapidly worsening cardiogenic shock with asymptomatic electrocardiographic changes and drastic drop in cardiac biomarkers, and a diagnosis of myocarditis as an immune-related adverse event was made. Although immediate methylprednisolone mini-pulse therapy followed by tapered prednisolone prevented mortality, extensive myocardial fibrosis with marked ejection fraction decline persisted as a sequela. Consequently, follow-up without treatment was instituted; however, much of the tumor response initially observed was maintained over several months. Conclusion: Physicians treating patients with immune checkpoint inhibitors should be aware of their potentially life-threatening cardiotoxic effects. This study emphasized the importance of a high index of suspicion, prompt diagnosis, and early intervention in patients who present with cardiac abnormalities and possible myocarditis after receiving immunotherapy.

Immune-related adverse event-myocarditis with marked ST-segment elevation requiring differentiation from COVID-19-induced myocarditis: a case report

Case report of an ST-elevation Myocardial Infarction-like presentation of an immune checkpoint (PD-1/PD-L1) inhibitor-associated myocarditis

Myocarditis associated with immune-checkpoint inhibitors diagnosed by cardiac magnetic resonance imaging

Immune checkpoint inhibitor–associated myocarditis: a systematic analysis of case reports

An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors

Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors

Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data

The Intrinsic Differences Between Immune Checkpoint Inhibitor Induced Myocarditis: A Retrospective Analysis of Real-World Data

Immune Checkpoint Inhibitor-Induced Myocarditis and Myositis in Liver Cancer Patients: A Case Report and Literature Review.

Immune myocarditis induced by sintilimab therapy: A case report

Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report

Clinical and electrocardiographic characteristics of immune checkpoint inhibitor-related myocarditis

A Retrospective Study of Immune Checkpoint Inhibitor-Associated Myocarditis in a Single Center in China.

Myocarditis: A Rare Complication of Immune Checkpoint Inhibitor Therapy

Prognosis of immune checkpoint inhibitor-related myocarditis: Retrospective experience of a single institution

[Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].

Immune Checkpoint Inhibitor-Related Myocarditis: Recognition, Surveillance, and Management

Acute cardiac manifestations under immune checkpoint inhibitors-beware of the obvious: a case report

Immune Checkpoint Inhibitors-related Myocarditis in Patients with Cancer: an Analysis of International Spontaneous Reporting Systems

A Case of Immune Checkpoint Inhibitor-Induced Probable Myocarditis and Treatment Response

Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data